23833299	673	Nathanson KL	Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).	Clinical cancer research 	2013	36
10648628	1017	Dickson MA	Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics.	Molecular and cellular biology	2000	241
7777060	1019	Lukas J	Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.	Nature	1995	182
8152487	1019	Nobori T	Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.	Nature	1994	206
9242437	1019	Schutte M	Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.	Cancer research	1997	136
12077343	1019	Rheinwald JG	A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status.	Molecular and cellular biology	2002	89
17047042	1019	Goldstein AM	High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.	Cancer research	2006	74
19609742	1019	Rao SK	A survey of glioblastoma genomic amplifications and deletions.	Journal of neuro-oncology	2010	46
21412932	1019	Birnbaum DJ	Genome profiling of pancreatic adenocarcinoma.	Genes, chromosomes and cancer	2011	43
22711607	1019	Cen L	p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.	Neuro-oncology	2012	34
24495407	1019	Young RJ	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.	Pigment cell and melanoma research	2014	25
25719666	1021	Waddell N	Whole genomes redefine the mutational landscape of pancreatic cancer.	Nature	2015	212
9018243	1027	Porter PL	Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.	Nature medicine	1997	135
7553621	1029	Herman JG	Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.	Cancer research	1995	241
7585152	1029	Merlo A	5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.	Nature medicine	1995	274
8153634	1029	Kamb A	A cell cycle regulator potentially involved in genesis of many tumor types.	Science	1994	337
9135016	1029	Rozenblum E	Tumor-suppressive pathways in pancreatic carcinoma.	Cancer research	1997	154
9776413	1029	Cairncross JG	Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.	Journal of the National Cancer Institute	1998	181
10072356	1029	Sharpless NE	The INK4A/ARF locus and its two gene products.	Current opinion in genetics and development	1999	107
10319873	1029	Barrett MT	Evolution of neoplastic cell lineages in Barrett oesophagus.	Nature genetics	1999	97
10416987	1029	Ishii N	Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.	Brain pathology	1999	155
10541553	1029	Schmitt CA	INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.	Genes and development	1999	135
11196170	1029	Zöchbauer-Müller S	Aberrant promoter methylation of multiple genes in non-small cell lung cancers.	Cancer research	2001	104
11544531	1029	Sharpless NE	Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.	Nature	2001	231
12789288	1029	Wu H	PTEN signaling pathways in melanoma.	Oncogene	2003	86
14722605	1029	Sharpless NE	Telomeres, stem cells, senescence, and cancer.	The Journal of clinical investigation	2004	112
15466178	1029	Ohgaki H	Genetic pathways to glioblastoma: a population-based study.	Cancer research	2004	282
15899794	1029	Rich JN	Gene expression profiling and genetic markers in glioblastoma survival.	Cancer research	2005	78
16905682	1029	Goldstein AM	Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.	Journal of medical genetics	2007	75
16964246	1029	Denoyelle C	Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway.	Nature cell biology	2006	97
17065427	1029	Ogino S	CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.	The Journal of molecular diagnostics 	2006	134
17326708	1029	Galipeau PC	NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.	PLoS medicine	2007	87
17334996	1029	Jönsson G	High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.	Genes, chromosomes and cancer	2007	64
18305067	1029	Leedham SJ	Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus.	Gut	2008	56
18688285	1029	Hacein-Bey-Abina S	Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.	The Journal of clinical investigation	2008	456
18688286	1029	Howe SJ	Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.	The Journal of clinical investigation	2008	321
19074898	1029	Solomon DA	Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.	Cancer research	2008	50
19593635	1029	Hollestelle A	Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.	Breast cancer research and treatment	2010	83
19718709	1029	Mohseny AB	Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.	The Journal of pathology	2009	71
19825961	1029	Ogino S	Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.	Clinical cancer research 	2009	92
20068183	1029	Schiffman JD	Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.	Cancer research	2010	86
20451455	1029	Marur S	HPV-associated head and neck cancer: a virus-related cancer epidemic.	The Lancet. Oncology	2010	283
20460471	1029	Jönsson G	Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.	Clinical cancer research 	2010	58
21129377	1029	Vasen HF	Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation.	Gastroenterology	2011	39
21248843	1029	Notta F	Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.	Nature	2011	154
21619050	1029	Li J	Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer.	Biochemistry	2011	38
21636552	1029	Raabe EH	BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.	Clinical cancer research 	2011	42
22067401	1029	Oberholzer PA	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.	Journal of clinical oncology 	2012	79
22084097	1029	Nagai H	Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2011	89
22256804	1029	Su F	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.	The New England journal of medicine	2012	200
23412337	1029	Sottoriva A	Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.	Proceedings of the National Academy of Sciences of the United States of America	2013	266
23470568	1029	Oshima M	Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.	Annals of surgery	2013	42
23663786	1029	Yang L	Diverse mechanisms of somatic structural variations in human cancer genomes.	Cell	2013	74
23677068	1029	Sekido Y	Molecular pathogenesis of malignant mesothelioma.	Carcinogenesis	2013	32
23887298	1029	Ross JS	Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.	Modern pathology 	2014	36
23907151	1029	Kanagal-Shamanna R	Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics.	Modern pathology 	2014	32
24127483	1029	Fabbri G	Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.	The Journal of experimental medicine	2013	26
24425785	1029	Li H	Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.	Molecular cancer research 	2014	21
24733792	1029	Kurian AW	Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment.	Journal of clinical oncology 	2014	68
24957142	1029	Moorman AV	A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.	Blood	2014	24
25009010	1029	De Mattos-Arruda L	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.	Annals of oncology 	2014	47
25010205	1029	Brohl AS	The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.	PLoS genetics	2014	53
25092538	1029	Kim PH	Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.	European urology	2015	19
25117714	1029	Ozawa T	Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma.	Cancer cell	2014	54
25223734	1029	Tirode F	Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.	Cancer discovery	2014	57
25479140	1029	Grant RC	Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.	Gastroenterology	2015	23
25503501	1029	Maxwell KN	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.	Genetics in medicine 	2015	24
25536104	1029	Churi CR	Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.	PloS one	2014	40
25584893	1029	Damsky W	mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.	Cancer cell	2015	15
25589618	1029	Li YY	Genomic analysis of metastatic cutaneous squamous cell carcinoma.	Clinical cancer research 	2015	17
25712460	1029	Chung CH	Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.	Annals of oncology 	2015	17
25822088	1029	Schulze K	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.	Nature genetics	2015	104
26099527	1029	Zucman-Rossi J	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.	Gastroenterology	2015	47
26192918	1029	Stachler MD	Paired exome analysis of Barrett's esophagus and adenocarcinoma.	Nature genetics	2015	30
26536169	1029	Cancer Genome Atlas Research Network.	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.	The New England journal of medicine	2016	69
26551670	1029	Wang L	Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.	Nature genetics	2015	24
26658419	1029	Roberts NJ	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.	Cancer discovery	2016	14
26830752	1029	Kamisawa T	Pancreatic cancer.	Lancet	2016	47
26873401	1029	Sawada G	Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.	Gastroenterology	2016	17
26912361	1029	Mavrakis KJ	Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.	Science	2016	19
27114589	1029	Vasen H	Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.	Journal of clinical oncology 	2016	16
27213815	1029	Dauch D	A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.	Nature medicine	2016	15
17187432	1499	Boyault S	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.	Hepatology	2007	191
19078924	1499	Bansal N	The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.	Cancer control 	2009	64
19525976	1846	Chitale D	An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.	Oncogene	2009	87
25150284	1956	Labussière M	Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.	Neurology	2014	29
23954893	3417	Chaturvedi A	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.	Blood	2013	43
19470474	3716	Mullighan CG	JAK mutations in high-risk childhood acute lymphoblastic leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2009	148
19686742	3845	Nosho K	A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers.	Gastroenterology	2009	53
19584151	4089	Blackford A	SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.	Clinical cancer research 	2009	91
22614978	4893	Colombino M	BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.	Journal of clinical oncology 	2012	72
12853964	5925	Sage J	Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.	Nature	2003	193
18211953	5925	Dimaras H	Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma.	Human molecular genetics	2008	58
18782450	5925	Herschkowitz JI	The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.	Breast cancer research 	2008	86
24569790	7015	Heidenreich B	Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.	Nature communications	2014	24
17289567	26038	Bagchi A	CHD5 is a tumor suppressor at human 1p36.	Cell	2007	112
25938782	53335	Basak A	BCL11A deletions result in fetal hemoglobin persistence and neurodevelopmental alterations.	The Journal of clinical investigation	2015	20
